Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer

Oncology

Trial design and analysis

Pharmacometrics

Mc Laughlin AM, Pan Y, Friberg Hietala S, Peigné S, Uema D, Zwirtes R, Dai D, Zhou D, Tajima N, Garimella T, Abutarif M, Hong Y